On 21 March, OMLYCLO received a ‘full marketing authorization’ from the European Commission(EC), almost two months after receiving a ‘recommendation for approval’ opinion from the Committee for Medicinal Products for Human Use(CHMP) of the European Medicines Agency(EMA).
As real gross domestic product(GDP) grew by 1.3% in the first quarter of this year compared to the previous quarter, the Bank of Korea raised this year’s economic growth rate from 2.1% to 2.5%.